Immunomedics (IMMU) Majority-owned Subsidiary Awarded US Patent for New Vaccine Technology Targeting Dendritic Cells
Immunomedics (Nasdaq: IMMU)
Keep a close eye on IMMU. The company reported after closing bell the issuance of U.S. patent no. 8,562,988 to its majority-owned subsidiary, IBC Pharmaceuticals, Inc., for "Novel Strategies for Improved Cancer Vaccines", protecting a new vaccine technology targeting dendritic cells for blood cancer treatment.
The new patent concerns methods and compositions for forming anti-cancer vaccine complexes created with the Company's proprietary DOCK-AND-LOCK(TM) method. The allowed claims cover the use of bispecific antibodies targeting CD74, the major histocompatibility complex class-II invariant chain, Ii, of immune cells, and CD20 to form a vaccine complex.
Because immune cells such as dendritic cells express high levels of CD74, the bispecific antibody-vaccine complex is capable of inducing an immune response against CD20-expressing cancer cells, killing, inhibiting the growth of, or eliminating the cancer cells.
This patent will expire in March 2026.
IMMU stock closed at $4.09 with a volume of 3,833,323 shares on Tuesday's trading session
IMMU is a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
Read Full Disclaimer at www.pennyomega.com/disclaimer
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.